--- title: "Pre-market hot trades in US stocks: VenHub Global pre-market down 7.17%; AST SpaceMobile pre-market down 4.43%" type: "News" locale: "en" url: "https://longbridge.com/en/news/286561304.md" description: "VenHub Global pre-market down 7.17%; AST SpaceMobile pre-market down 4.43%; HCW Biologics pre-market up 202.67%; Dreamland pre-market up 112.52%; Murano Global BV pre-market up 64.33%" datetime: "2026-05-15T12:02:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286561304.md) - [en](https://longbridge.com/en/news/286561304.md) - [zh-HK](https://longbridge.com/zh-HK/news/286561304.md) --- # Pre-market hot trades in US stocks: VenHub Global pre-market down 7.17%; AST SpaceMobile pre-market down 4.43% **Pre-market Hot Trades in US Stocks** VenHub Global, down 7.17% in pre-market trading, has had no significant news recently. The trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. AST SpaceMobile is down 4.43% in pre-market trading. Based on recent key news: 1. On May 12, AST SpaceMobile announced its first-quarter financial report, with revenue of $14.73 million, below analysts' expectations of $39 million, leading to a drop in stock price. The loss per share was $0.66, far exceeding the expected $0.23. Source: Barron’s 2. On May 12, analysts expressed concerns about AST SpaceMobile's future launch plans, particularly its reliance on launch services from Blue Origin and SpaceX. Blue Origin experienced a mishap during an April launch mission, affecting investor confidence. Source: MoneyDJ 3. On May 12, analysts lowered AST SpaceMobile's average target price from $89.62 to $89.12, reflecting the market's cautious attitude towards its future performance. Source: FactSet The satellite communication industry faces launch risks and valuation pressures. **Top Gainers in Pre-market US Stocks** HCW Biologics is up 202.67% in pre-market trading. Based on recent key news: 1. On May 14, HCW Biologics released its financial report for the first quarter of 2026, showing significant progress in the field of innovative combination immunotherapy. The stock price surged significantly after the report was released. 2. On May 14, HCW Biologics discovered in its IND-enabled research that its drug HCW11-040 can prevent bronchopulmonary dysplasia (BPD), with expectations to complete the research and submit the IND application in the second half of 2027. This discovery has boosted market confidence in the company's future development, driving the stock price up. 3. On May 15, analysts gave HCW Biologics a "Buy" rating, with Wall Street's 12-month price target set at $2.00, approximately 472.4% higher than the closing price of $0.35 on May 13. This optimistic analyst rating further stimulated the rise in stock price. The biotechnology sector has performed strongly recently, with significant capital inflows. Dreamland is up 112.52% in pre-market trading. Based on recent key news: 1. On May 13, Dreamland's stock price surged by 126.92%, with a trading volume of approximately $219 million, indicating an extremely rare scale of capital inflow. Technical indicators show bullish signals, but considering the extreme increase, a more comprehensive analysis is needed. On the news front, there are no significant positive developments in the industry, and the stock price surge may be related to company-level catalytic factors, such as merger rumors or project signings Source: Benzinga 2. On May 12, Dreamland signed a memorandum of understanding with LinkFung Innovation to explore the development of an AI platform. This move aims to enhance services through technology and expand market influence. Source: Benzinga 3. On May 14, technical indicators showed that the stock price was severely overbought, with an RSI of 97.75, and the stock price far exceeded key moving averages, leading to heightened market optimism. Source: Benzinga The film and entertainment industry has not seen any significant positive news recently. Murano Global BV rose 64.33% in pre-market trading. Based on recent key news: 1. On May 11, Murano Global Investments disclosed that CEO Sacal Cababie Elias holds 69,152,609 common shares, demonstrating confidence from the company's leadership in its future, which drove the stock price up. 2. On May 11, Murano Global Investments appointed Oscar Jazmani Mendoza Escobar as Chief Financial Officer, and the market's expectations for the new management team boosted investor confidence, promoting the stock price increase. 3. On May 11, Murano Global Investments appointed Marcos Sacal Cohen as Chief Operating Officer and Director, further solidifying the company's management team and enhancing market confidence in the company's operational capabilities, resulting in a stock price increase. The U.S. stock market has recently experienced increased volatility, and risks should be monitored ### Related Stocks - [VHUB.US](https://longbridge.com/en/quote/VHUB.US.md) - [ASTS.US](https://longbridge.com/en/quote/ASTS.US.md) - [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md) - [TDIC.US](https://longbridge.com/en/quote/TDIC.US.md) - [MRNO.US](https://longbridge.com/en/quote/MRNO.US.md) ## Related News & Research - [$100 Invested In AST SpaceMobile 5 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/286971455.md) - [SpaceX sets June 12 IPO at up to $2T valuation](https://longbridge.com/en/news/286847957.md) - [TGT Stock Alert: What to Know as Target Taps Former Walmart Exec](https://longbridge.com/en/news/286957668.md) - [Should you invest $1,000 in AGNC Investment right now?](https://longbridge.com/en/news/286802595.md) - [Why RKLB and ASTS Stocks are Down Today](https://longbridge.com/en/news/286946861.md)